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Background: LEDGINs are novel allosteric HIV integrase (IN) inhibitors that target the lens epithelium-derived
growth factor (LEDGF)/p75 binding pocket of IN. They block HIV-1 integration by abrogating the interaction
between LEDGF/p75 and IN as well as by allosterically inhibiting the catalytic activity of IN.
Results: Here we demonstrate that LEDGINs reduce the replication capacity of HIV particles produced in their
presence. We systematically studied the molecular basis of this late effect of LEDGINs and demonstrate that HIV
virions produced in their presence display a severe replication defect. Both the late effect and the previously
described, early effect on integration contribute to LEDGIN antiviral activity as shown by time-of-addition, qPCR and
infectivity assays. The late effect phenotype requires binding of LEDGINs to integrase without influencing
proteolytic cleavage or production of viral particles. LEDGINs augment IN multimerization during virion assembly or
in the released viral particles and severely hamper the infectivity of progeny virions. About 70% of the particles
produced in LEDGIN-treated cells do not form a core or display aberrant empty cores with a mislocalized electron-
dense ribonucleoprotein. The LEDGIN-treated virus displays defective reverse transcription and nuclear import steps
in the target cells. The LEDGIN effect is possibly exerted at the level of the Pol precursor polyprotein.
Conclusion: Our results suggest that LEDGINs modulate IN multimerization in progeny virions and impair the
formation of regular cores during the maturation step, resulting in a decreased infectivity of the viral particles in the
target cells. LEDGINs thus profile as unique antivirals with combined early (integration) and late (IN assembly)
effects on the HIV replication cycle.
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HIV-1 integrase (IN) is responsible for the insertion of
viral reverse transcribed double-stranded genomic DNA
into host chromatin. The integration process proceeds
through two canonical reactions called 3’ processing and
strand transfer [1]. The first reaction requires at least a
dimer of IN on each viral DNA end, while a dimer of di-
mers binding both ends is required for the second [2,3].* Correspondence: Zeger.debyser@med.kuleuven.be
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reproduction in any medium, provided the orIt is generally believed that a dynamic equilibrium be-
tween different oligomeric states of IN in time and space
is essential for the completion of the HIV life cycle [2,3].
A shift in the multimerization equilibrium of IN may
perturb its catalytic activities and structural functions in
the preintegration complexes (PICs) resulting in defect-
ive integration [4]. Integration of lentiviruses including
HIV is dictated by the specific interaction between IN
and the cellular cofactor lens epithelium-derived growth
factor (LEDGF/p75) that acts as a molecular tether
linking IN to the chromatin [5-10].
Integrase is an attractive target for drug development.
All HIV IN inhibitors currently in the clinic belong toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 LEDGINs impair replication capacity of HIV-1
produced by HuT78IIIB cells. HIV-1IIIB was produced by persistently
infected HuT78IIIB cells in the presence of different concentrations of
AZT, raltegravir, CX04328, CX05045, ritonavir or DMSO.
(A) Replication capacity of these viruses was assayed in MT-4 cells
and data represent virus titer as determined by 50% tissue culture
infectivity dose (logTCID50/ml) (mean values ± standard deviations;
n = 3). (B) Kinetics of p24 production over successive days was
measured for cells treated with 10-fold EC50 of the inhibitors (n = 2).
*p<0.05, **p < 0.01; 2-way ANOVA.
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target the active site of IN bound to processed viral
DNA. This class includes raltegravir, elvitegravir and
dolutegravir (a second-generation INSTI in phase-III
clinical trials) [11], all potent antivirals with high safety
profiles. However, resistance readily emerges in patients
against these inhibitors. Therefore, development of next-
generation IN inhibitors preferably targeting alternative
sites of the enzyme is a major priority in the field of
antiviral research.
In search of such inhibitors, we recently discovered a
novel class of small molecule IN inhibitors targeting the
LEDGF/p75 binding pocket located at the dimer inter-
face of the IN catalytic core domain (CCD) [12]. The
compounds within this class are hence referred to as
LEDGINs (LEDGF/p75-IN interaction site) [13]. Due to
the allosteric nature of LEDGINs, recently it has been
proposed to change the name to ALLINIs (allosteric
integrase inhibitors) [14]. ALLINIs though refers to all
inhibitors which do not directly interfere with the cata-
lytic site of integrase. Thus it is a generalized name of
different classes of integrase inhibitors with distinct
mechanisms of actions as reviewed by Neamati et al.
[15], and does not refer to the specific and novel mech-
anism of action of LEDGINs. LEDGINs inhibit replica-
tion of all HIV-1 clades tested at submicromolar
concentration and show no cross-resistance with INSTIs
[16]. Apart from disrupting the LEDGF/p75-IN inter-
action, LEDGINs and their analogs allosterically inhibit
the catalytic activities of IN by perturbing its
multimerization state [12,14,16,17]. Furthermore, we re-
cently reported that LEDGINs seem to affect the replica-
tion capacity of progeny virions [16]. The objectives of
the current study were to investigate the molecular basis
of the antiviral activity of LEDGINs in the late stage of
HIV-1 replication and pinpoint the defects in the pro-
geny virions and during the subsequent viral life cycles
in target cells. We demonstrate that LEDGINs are able
to engage IN in the context of the Pol polyprotein and
modulate its multimerization. LEDGINs augment
intravirion IN multimerization and prevent the forma-
tion of regular cores in a significant proportion of viral
particles thereby strongly impairing the replication cap-
acity without affecting proteolytic cleavage or genomic
RNA (gRNA) packaging.
Results
Replication capacity of progeny virus grown in the
presence of LEDGINs is reduced
The replication capacity of HIV-1 particles produced by
chronically infected HuT78 cells in the presence of
LEDGINs seems to be impaired [16]. Before determining
the molecular basis of the late effect of LEDGINs, we
corroborated this observation by examining thereplication capacity of virus produced in the presence of
LEDGINs. HuT78 cells chronically infected with HIV-1
IIIB (referred herein as HuT78IIIB cells) were grown in
the presence of different concentrations of LEDGINs
(CX04328; EC50 = 2.35 μM or CX05045; EC50 = 0.76
μM) [12]. As controls, we included antivirals that inhibit
HIV reverse transcription (AZT; EC50 = 0.02 μM), inte-
gration (raltegravir; EC50 = 0.006 μM) and proteolytic
maturation (ritonavir; EC50 = 0.06 μM). The 50% effect-
ive concentrations (EC50) were determined in an MTT/
MT-4 assay and used to calculate the concentration of
compounds added in the various assays.
The replication capacity of HIV-1IIIB produced by
HuT78IIIB in the presence of increasing concentrations
of AZT or raltegravir was evaluated in MT-4 cells. Repli-
cation of progeny virus was not affected compared to
DMSO-treated cells with an average infectivity of 7.3
±0.62 log TCID50/ml (Figure 1A). In contrast, viruses
produced in the presence of ritonavir or LEDGINs
displayed a concentration dependent impairment of pro-
ductive infection. At concentrations of 50-fold their
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pathic effect of viruses more than 100-fold in compari-
son with viruses produced in the presence of DMSO,
AZT or raltegravir (2-way ANOVA, p<0.01) (Figure 1A).
Concomitantly, we monitored the kinetics of virus pro-
duction by HuT78IIIB cells in the presence of com-
pounds at concentrations equal to 10-fold the EC50
value (Figure 1B). Except for ritonavir, none of the tested
inhibitors affected the accumulation of p24 in the super-
natant as monitored by p24 ELISA.
LEDGINs inhibit multiple steps in HIV replication
LEDGINs are known to target IN at the LEDGF/p75-IN
interaction interface and block integration [12]. BecauseFigure 2 Systematic evaluation of the multiple effects of LEDGINs on
and infectivity assays to determine the late effect of LEDGINs. (B, C) Detaile
in HeLaP4 cells as determined by measuring beta-galactosidase activity 24
measuring p24 72 hpi (mean values ± standard deviations; n = 2). (D) Infec
presence CX05045 (HIVCX05045) or DMSO (HIVDMSO) as measured by Firefly l
measurements for three dilutions of inocula normalized for p24 antigen are
circles and integrated copies in MT-4 cells are shown (mean values ± stand
-addition (TOA) analysis in MT-4 cells for (F) inhibition of single round repli
progeny virions was determined 4 dpi by p24 ELISA in the supernatants. Ti
for each compound. As expected, AZT loses activity at 4–7 hpi and raltegra
Ritonavir affects p24 production and virus infectivity at around 20–26 hpi. C
assaying single round infection, (G) whereas the late effect is evidenced on
in its presence (t1/2 = 24.5 h). Data represent normalized inhibition to the DLEDGINs also curtail the replication capacity of virus pro-
duced from chronically infected HuT78 cells (Figure 1A),
we set up a series of assays to unambiguously dissect
their effects during the different stages of HIV replica-
tion. First, we produced virus by transfection of 293T
cells in the presence of CX05045 (5 μM), raltegravir
(0.03 μM), ritonavir (0.3 μM) or DMSO (no-inhibitor)
and investigated infectivity of the progeny virions in dif-
ferent cells (Figure 2A). To eliminate the possibility
that compound is carried over in the supernatant together
with the virus, we also used viruses that were exten-
sively washed and pelleted by ultracentrifugation. We
then examined the replication capacity of the viruses in
HeLaP4 and MT-4 cells by measuring beta-galactosidaseHIV-1 replication. (A) Schematic representation of virus production
d analysis of the late effect of LEDGINs on the replication of NL4.3 (B)
hpi (mean values ± standard deviations; n = 2), (C) in MT-4 cells by
tivity of HIV-1-IN-eGFP/VSV.G pseudovirus [27] generated in the
uciferase (fLuc) activity (mean values ± standard deviations of triplicate
shown). (E) qPCR analysis for the kinetics of late RT product, 2-LTR
ard deviations of triplicate measurements are plotted). (F, G) Time-of
cation determined at 31 hpi or (G) loss of replication capacity of the
me (t1/2, h) of compound addition yielding 50% inhibition is indicated
vir at 11–12 hpi coinciding with RT and integration steps, respectively.
X05045 profiles as (F) an integration inhibitor (t1/2 = 12.2 h) when
ly when measuring replication capacity of the progeny virions released
MSO control (set at 100%).
Table 1 Stage-specific antiviral activity of LEDGINs
EC50 (μM)
Multiple rounda Early stageb Late stageb
CX05045 1.14±0.32 4.45±2.34 1.46±0.01
Raltegravir 0.006±0023 0.0031±0.0013 > 3
Ritonavir 0.05±0.0027 >3 0.04±0.006
a Effective concentration required to reduce HIV-1 induced cytopathic effect
by 50% in MT-4 cells as determined by an MTT/MT-4 assay. b Effective
concentration required to reduce Tat-driven beta-galactosidase expression by
50% in HeLaP4 cells at 24 hpi. Mean values ± standard deviations from at least
two independent experiments are shown.
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72 h post infection (hpi), respectively. Unlike raltegravir
and irrespective of the extensive washing, ritonavir and
CX05045 profoundly impaired virus replication when
added during production (Figure 2B, C), ruling out that
the effect is caused by the carry-over of compound in
the supernatant. To further corroborate the late effect
of LEDGINs on infectivity of HIV-1, we produced single
round VSV.G pseudotyped HIV pseudovirus in the
presence or absence of CX05045 and measured the fire-
fly luciferase (fLuc) activity in MT-4 cells. Addition of
CX05045 during production resulted in lower fLuc activity
(e.g. >300-fold for the 1:1 dilution) compared to the
DMSO-treated virus (Figure 2D).
We then examined the replication cycle of HIV in
time using qPCR analysis of viral DNA species [18] and
time-of-addition (TOA) [19]. Consistent with our previ-
ous report on the mode of action of LEDGINs in the
early stage of HIV replication [12], CX05045 blocks
HIV-1 integration without affecting the upstream repli-
cation events (Figure 2E). While only AZT inhibited RT
activity, both CX05045 and raltegravir significantly
blocked integration resulting in an accumulation of 2-
long terminal repeat (2-LTR) circles at 24 hpi (Figure 2E),
a hallmark of IN inhibitors [12,20,30].
Next, we designed and carried out a TOA experiment
in MT-4 cells in which the antivirals were added every
hour post infection and the supernatants were harvested
31 hpi, the average duration of a single HIV replication
cycle in laboratory-adapted T cells [21,22]. Theoretically,
addition of a drug after the completion of the step
targeted will result in a lack of inhibition and hence
p24 protein will accumulate in the supernatant. As
such, the targeted step by CX05045 or the control inhib-
itors (AZT, raltegravir and ritonavir) was monitored by
quantifying p24 protein in the supernatants harvested
from the TOA experiment (Figure 2F, Additional file 1:
Table S1). The average time delay post infection (t0)
when addition of the compound retained 50% inhibition
of HIV-1 replication (t1/2) was calculated [23]. Accord-
ingly, we found t1/2 of ~ 7.0, 12.4, 12.1 and 25.7 hpi for
AZT, raltegravir, CX05045 and ritonavir, respectively
(Figure 2F, Additional file 1: Table S1). These correspond
to RT (AZT), integration (raltegravir and the early effect
of CX05045) and proteolytic maturation steps (ritonavir).
Subsequently, to pinpoint the late effect of LEDGINs, we
used the supernatants harvested from the TOA experi-
ment and evaluated the replication capacity of the pro-
geny virions. To do this, we infected new MT-4 cells
with the supernatants and quantified p24 protein in the
supernatants 4 days post infection (dpi) (Figure 2G,
Additional file 1: Table S1). As expected, cells incubated
with supernatants harvested from cells treated with AZT
(beyond 4 hpi) or raltegravir (beyond 11 hpi) in theTOA experiment displayed comparable productive infec-
tion as the control virus (DMSO-treated) infected cells,
coinciding with their targets i.e. RT and integration, re-
spectively (Figure 2G). On the other hand, viruses pro-
duced in the presence of ritonavir added as late as 21 hpi
in the TOA experiment were less infectious, correspond-
ing to the proteolytic maturation block (Figure 2G).
Remarkably, when monitoring replication capacity of vi-
ruses produced in the presence of CX05045, we found
that the viruses displayed impaired replication capacity
when CX05045 was added as late as 24 hpi (Figure 2G).
These results clearly establish that LEDGINs affect both
integration and late stages of HIV replication. To assess
the relative contribution of both effects, we determined
EC50 values for the early and the late effect using a beta-
galactosidase assay (Table 1). CX05045 blocks HIV inte-
gration and virion infectivity in HeLaP4 cells with EC50
values of 4.45±2.34 μM and 1.46±0.01 μM, respectively,
indicating that both effects contribute to the overall inhi-
bition of multiple round HIV replication (1.14±0.32 μM)
(Table 1).
LEDGINs do not affect virion gRNA packaging or
proteolytic cleavage but interfere with the assembly of
regular mature cores
We next explored potential mechanisms underlying the
late effect of LEDGINs. We first examined the impact of
CX05045, raltegravir or ritonavir on the efficiency of
gRNA packaging by RT-qPCR analysis and on the
morphology of HIV-1 particles by transmission electron
microscopy (TEM) (Figure 3A-C). None of the inhibitors
interfered with gRNA packaging (1-way ANOVA,
p>0.05) (Figure 3A).
TEM analysis of the morphology of viral particles at
or near the plasma membrane clearly demonstrated that
ritonavir affected virus maturation rendering almost all
of the particles released to be immature (Figure 3B) [24].
Interestingly, while no morphological differences to the
DMSO control have been noticed in the raltegravir
treated sample, particles with a mislocalized electron-
dense ribonucleoprotein (RNP) and particles lacking a
core structure were frequently observed in the CX05045
Figure 3 Characterization of the replication defect induced by LEDGIN treatment. (A) Viral gRNA and total RNA extract of the respective
producer cells as quantified by RT-qPCR. Mean values ± standard deviations of triplicate measurements from two experiments are shown. (B, C)
Morphology of viral particles produced from HuT78IIIB cells grown in the presence of DMSO, raltegravir, CX05045 or ritonavir. (B) Representative
TEM overview images are presented. (C) TEM images exemplifying regular and aberrant particle morphology in the LEDGIN treated sample.
(D) The particles were classified and quantified according to their morphology in thin section EM. The percentage was calculated relative to the
total number of particles analyzed (200–400 particles per condition). The ritonavir-treated sample contained > 90% immature particles
(not shown). (E, F) Western blot analysis of viral proteins in HuT78IIIB producer cells or the corresponding cell-free viruses produced in the
presence of the indicated compounds. β-tubulin was used as loading control. Scale bars represent 500 nm.
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fying 200–300 visualized particles per sample revealed
that about 26% of the virions display an aberrant empty
core with an external RNP frequently attached to the
virus membrane and rarely to the empty core. The
empty core was usually thinner than regular cores and
often bar shaped. In 37.5% of the particles no core was
visible at all and the electron dense RNP complex was
attached to the virus membrane (Figure 3C). A regular
core with the RNP generally localized at the broader site
of the conical core was present in only 27% of the
CX05045 treated particles but in 85% of the DMSO con-
trol and 86.5% of the raltegravir sample (Figure 3D).
To investigate the viral precursor polyprotein process-
ing pattern, Western blot analysis was performed on
samples from virus producer HuT78IIIB cells as well as
on virus lysate produced in the presence of DMSO,
raltegravir, CX05045 or ritonavir. In contrast to the
expected effect of ritonavir on viral protein processing,
we observed no significant effect on Gag polyprotein
processing in the producer cells (Figure 3D) and on virusreleased in the supernatants (Figure 3E), correlating with
p24 (Figure 1B) and morphology analysis (Figure 3B, C).
Taken together, these data indicate that LEDGINs impair
HIV infectivity (i.e. a late effect) through a mechanism
distinct from proteolytic cleavage or gRNA packaging.
LEDGINs clearly affect the formation of a regular ma-
ture core containing the RNP.
The late effect of LEDGINs requires a direct interaction
with HIV-1 integrase
LEDGINs, the result of structure-based drug design
targeting IN, were shown to bind to the LEDGF/p75
binding pocket in IN by crystallography [12]. If the im-
pairment of HIV replication capacity by LEDGINs is me-
diated by a direct interaction with IN at the LEDGF/p75
binding pocket, productive infection of the LEDGIN-
resistant strain NL4.3A128T, [12] should not be hampered
by addition of LEDGINs during virus production. In line
with this, we produced NL4.3A128T and different wild
type (WT) strains (NL4.3, HXB2D and YU-2) in the
presence of CX05045, raltegravir, ritonavir or DMSO,
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cells, peripheral blood mononuclear cells (PBMC) or
monocyte derived macrophages (MDM) as shown in
Figure 2A. We compared the replication of WT and
NL4.3A128T viruses in HeLaP4 (Figure 4A), MT-4 cells
(Figure 4B) and PBMC (Figure 4C). The replication of
NL4.3 and HXB2D produced in the presence of
CX05045 was reduced 200- and 1,750-fold in HeLaP4
and 200- and 2,600-fold in MT-4 cells, respectively,
compared to DMSO or raltegravir pretreatment (2-way
ANOVA, p<0.001) (Figure 4A, B). In stark contrast,
NL4.3A128T replication was unaffected (2-way ANOVA;
p>0.05) (Figure 4A, B). As expected, all HIV-1 strains
produced in the presence of ritonavir displayed a statis-
tically significant 10- to 30-fold drop in viral replication
in HeLaP4 and MT-4 cells (2-way ANOVA, p<0.001)
(Figure 4A,B).Figure 4 Reduction of virion replication capacity by LEDGINs is integr
replication capacity of different HIV-1 strains (NL4.3, LEDGIN-resistant NL4.3
galactosidase activity 24 hpi (n = 2), (B) in MT-4 cells by calculating the TCI
supernatant (n = 2–4). (D) Effect of CX05045 on HIV-2 and SIVmac251 produc
determined by scoring CPE in MT-4 cells on day 5 postinfection as determ
standard deviation. **p < 0.001; 2-way ANOVA.Of note, in activated human PBMC isolates, X4-tropic
HIV-1 (NL4.3, HXB2D) hardly replicated when pro-
duced in the presence of either CX05045 or ritonavir
compared to DMSO or raltegravir (Figure 4C). Replica-
tion of NL4.3A128T in PBMC was only impaired when
produced in the presence of ritonavir but not CX05045
(Figure 4C). To further confirm the specificity of the late
effect of LEDGINs, we also tested HIV-2 (HIV-2EHO and
HIV-2ROD) and SIVmac251 (Figure 4D). These viruses
have a methionine residue at position 128 of their INs,
resulting in a natural resistance to LEDGINs [12]. Con-
sistent with our hypothesis, CX05045 did not affect the
replication capacity of HIV-2 or SIVmac251 (Figure 4D).
We also observed severely hampered productive infec-
tions of X4- (NL4.3 and HXB2D) and R5-tropic (YU-2)
viruses in MT-4 cells and MDM, respectively, when
quantifying the p24 level in the supernatants overase dependent. Detailed analysis of the late effect of LEDGINs on the
A128T or HXB2D): (A) in HeLaP4 cells as determined by measuring beta-
D50/ml 5 dpi (n = 4), and (C) in PBMC by monitoring p24 level in the
tion and infectivity. The replication capacity of the viruses was
ined by relative to TCID50/ml (n = 2). All data represent mean values ±
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tively, these results suggest that the late antiviral effect of
LEDGINs is mediated through a direct interaction withFigure 5 Systematic evaluation of the multiple effects of LEDGINs on
species evaluating early replication events (entry to integration) are shown
measured by RT-qPCR analysis of gRNA isolated 2 h after synchronized infe
efavirenz, inhibits entry of both HIVDMSO and HIVCX05045. Heat-inactivated vi
deviation from three independent experiments are shown. (B, C) qPCR ana
HIVDMSO or HIVCX05045 in the presence or absence of efavirenz (EFAV) or ral
controls. There is a five-fold less RT products in cells infected with HIVCX050
viruses. (D, E) 2-LTR circle and integrated copies kinetics are shown. HIVDMS
evidenced by the accumulation of 2-LTR circles in cells treated with raltegr
translocate into the nucleus as shown by background integrants. This resul
circles when cells were treated with raltegravir (HIVCX05045+RAL). Mean valu
HIV preintegration complex (PIC) nuclear import. Percentage of nuclear ver
HIVDMSO (black bars, n = 71) is shown. More than 50% of cells infected with
nucleus. In contrast, 2-7% of fluorescently labeled PICs were detected in th
inset, the cumulative probability of nuclear PICs is plotted for HIVCX05045 (gr
computed using the Kolmogorov-Smirnov test, p < 0.0001).the LEDGF/p75 binding pocket on IN without affec-
ting proteolytic cleavage or gRNA packaging (Additional
file 1: Figure 2SA,B).HIV-1 replication. (A-E) (RT)-qPCR analyses for gRNA and viral DNA
. (A) HIVCX05045 enters cells as efficient as the control (HIVDMSO) virus as
ction of MT-4 cells. As expected, addition of DS10000, but not
rus preparation was used as negative control. Mean values ± standard
lysis for early and late RT product kinetics in MT-4 cells infected with
tegravir (RAL) added during infection as RT and integration inhibitor
45 compared to HIVDMSO and efavirenz blocked the RT activity of both
O has normal nuclear import as well as integration which are
avir. In stark contrast to HIVDMSO, the PICs of HIVCX05045 did not
t was further supported by the lack of the accumulation of 2-LTR
es ± standard deviations for triplicate measurements. (F) Analysis of
sus total PICs in cells infected with HIVCX05045 (gray bars, n = 72) or
HIVCX05045 did not contain any fluorescently labeled PIC in the
e nucleus of more than 50% of cells infected with HIVDMSO. In the
ay) and HIVDMSO (black). The empirical distribution function was
Desimmie et al. Retrovirology 2013, 10:57 Page 8 of 16
http://www.retrovirology.com/content/10/1/57Virions generated in the presence of LEDGINs display
replication defects in reverse transcription and nuclear
import
To pinpoint the replication defect(s) of virus produced
in the presence of CX05045 during the subsequent repli-
cation cycle, we produced HIV-1IIIB in the presence of
CX05045 (HIVCX05045) or DMSO (HIVDMSO) and
infected MT-4 cells after normalizing for p24 protein.
Next, (RT)-qPCR analyses were carried out on cellular
extracts obtained at different time points after infection
to assess the effect on virus entry and early replication
events. HIVCX05045 entered cells as efficiently as
HIVDMSO in a synchronized infection as determined by
quantification of gRNA by RT-qPCR analysis at 2 hpi
(Figure 5A). As expected, heat inactivation of the virus
or addition of the entry inhibitor DS10000, but not the
RT inhibitor efavirenz, resulted in reduced gRNA copy
number (Figure 5A).
We next examined the RT step by profiling viral DNA
synthesis kinetics using qPCR analysis. Compared to
HIVDMSO, we observed a five-fold drop in the levels of
both early and late reverse transcripts in from
HIVCX05045 infected cells extracts at 12 hpi (Figure 5B, C).
Efavirenz blocked reverse transcription of both viruses
as evidenced by background level of both early and
late RT products (Figure 5B, C), demonstrating that
HIVCX05045 carries functional RT. Of note, CX05045 in-
hibits RT neither in vitro (data not shown) nor in vivo
(Figure 2E) [12]. Compared to HIVDMSO infected cells,
background levels of 2-LTR circles (Figure 5D) and inte-
grated copies (Figure 5E) were evidenced in cells infected
with HIVCX05045, suggesting that the virus displays
additional defects at the nuclear import step. As expected,
the integration block incurred by raltegravir during in-
fection was accompanied by an increase in 2-LTR circles
in cells infected with HIVDMSO (HIVDMSO+RAL; more
than 20-fold higher circles compared to HIVDMSO at
24 hpi). However, we observed a background level of 2-
LTR circles in HIVCX05045 infected cells, which remained
identical even after raltegravir treatment (only 1.4-fold
increase compared to untreated HIVCX05045 at 24 hpi)
(Figure 5D), suggesting that there is little or no viral
cDNA translocated into the nucleus.
The reduced number of 2-LTR circles raised the ques-
tion whether HIVCX05045 is also defective for nuclear im-
port of the PIC, an event believed to be at least partially
dependent on the dynamic interaction between IN car-
ried in the PIC and karyopherins [25,26]. To address this
issue, we performed a nuclear PIC import assay using
fluorescently labeled HIV-1 particles [27]. We produced
VSV.G pseudotyped particles, carrying fluorescently la-
beled IN (IN-eGFP) through Vpr-mediated transin-
corporation, in the presence of CX05045 (HIVCX05045)
or DMSO (HIVDMSO). HeLaP4 cells were infected witheither HIVCX05045 or HIVDMSO after normalizing for p24
antigen. The catalytically inactive IND64E encoded by the
proviral construct was successfully transcomplemented
by the Vpr-fused IN-eGFP as determined by fLuc activity
at 48 hpi (Figure 2D). In two independent experiments,
the cellular distribution of the PICs was analyzed in
HeLaP4 cells at 7 hpi and the number of nuclear and
total PICs was quantified by confocal microscopy. For
HIVDMSO and HIVCX05045 infected samples, 71 and 72
cells were analyzed, respectively. We detected 7.1 ±
0.83% and 0.45 ± 0.13% of fluorescently labeled PICs in
the nucleus for HIVDMSO or HIVCX05045, respectively
(Figures 5F, Additional file 1: Figure S3). In addition, an
analysis of the cumulative distribution probability revealed
a statistically significant difference between HIVDMSO
and HIVCX05045 (p<0.0001; non-parametric two-tailed
Kolmogorov-Smirnov test) (Figure 5F, inset). Taken to-
gether, these data demonstrate that LEDGIN-induced loss
in infectivity is based on defects in reverse transcription
and nuclear import.
LEDGINs modulate IN multimerization in the nascent
viral particles
During progeny virion assembly and budding, IN is part
of the precursor Gag-Pol polyprotein. As LEDGINs are
able to enhance IN multimerization in vitro [16], we hy-
pothesized that the multimerization of the precursor Pol
polyprotein may similarly be influenced by LEDGINs
through their specific interaction with IN and thereby
impacting the generation of infectious particles. Using
an AlphaScreen protein-protein interaction (PPI) assay,
we examined the effect of CX05045 on Pol polyprotein
multimerization using recombinant Glutathione S-
Transferase tagged (GST)-Pol and His-Maltose-Binding
Protein (MBP)-tagged Pol polyproteins both containing
a catalytically dead protease (PRD25N). We observed that
CX05045 strongly enhanced Pol multimerization in a
concentration-dependent manner with an EC50 of 8.7
nM (95% CI 5.7-13.4), whereas the raltegravir and
DMSO controls had no effect on Pol multimerization
(Figure 6A). These results indicate that LEDGINs are
able to interact with IN as part of the precursor Pol
polyprotein and modulate its multimerization.
Next we investigated whether LEDGINs can perturb
the dynamics of IN multimers in nascent virions. To ad-
dress this issue, we set up an assay based on single-
molecule Förster Resonance Energy Transfer (FRET)
(Borrenberghs et al., unpublished results). Fluorescently
labeled chimeric HIV particles (herein referred to as
HIV-INWT) were produced using Vpr-mediated trans-
incorporation of IN-mTFP1 (FRET donor) and IN-
mVenus (FRET acceptor) in the presence of DMSO,
CX05045 or raltegravir. The fluorescence intensity of IN
donor per virion was quantified before and after
Figure 6 LEDGINs enhance multimerization of HIV integrase. (A) Direct and specific interaction of LEDGINs with HIV-1 Pol polyprotein.
(A) Titration of CX05045 or raltegravir against a constant background of 33 nM His-MBP-sPol-PRD25N and 33 nM GST-sPol-PRD25N. DMSO (vehicle)
included as no-inhibitor control. Only CX05045 was able to enhance the Pol-Pol multimerization with an EC50 of 8.7 nM (95% CI 5.7-13.4). Data
represent mean values ± standard deviations of duplicate measurements in two independent experiments. (B, C) FRET analysis of IN
multimerization in the virions. Histograms were plotted from pooled data of two independent experiments for (B) wild type HIV-1 (HIV-INWT) and
(C) LEDGIN-resistant (HIV-INA128T) virions. (B) FRET ratios for populations of fluorescent HIV-INWT virions produced in the presence of DMSO (dark
gray bar), CX05045 (light gray bar) or RAL (hatched bar) along with the respective normal distribution fits for DMSO (dark line), RAL (light gray line)
and CX05045 (broken line) are shown. The calculated mean and 95% CI of the FRET ratios for HIV-INWT are 1.25 (95% CI 1.23-1.28) (DMSO), 1.22
(95% CI 1.19-1.25) (RAL) and 1.43 (95% CI 1.42-1.45) (CX05045). (C) FRET ratios for populations of fluorescent HIV-INA128T virions produced in the
presence of DMSO (dark gray bar) or CX05045 (light gray bar) along with the respective normal distribution fits for DMSO (dark gray line) and for
CX05045 (broken line) are shown. The calculated mean and 95% CI of the FRET ratios for HIV-INA128T when produced in the presence or absence
of CX05045 are 1.23 (95% CI 1.21-1.25) and 1.26 (95% CI 1.24-1.27), respectively. A mean FRET ratio that equals unity means no FRET. *p <0.05;
Student t test.
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internal reflection and quantitative super-resolution
localization microscopy. As shown in Figure 6B the
FRET ratio, which is a measure of the amount of
dequenching of the IN-donor after photobleaching of
IN-acceptor, is significantly larger than unity when vi-
rions were produced in the presence of DMSO with a
mean of 1.25 (95% CI 1.23-1.28), proving that IN
multimerization in the virion can be measured with this
assay. HIV-INWT virions produced in the presence of
raltegravir showed a similar mean FRET ratio of 1.22
(95% CI 1.19-1.25). When virions were produced in the
presence of CX05045, the mean FRET ratio increased to
1.43 (95% CI 1.42-1.45) (p<0.05), strongly suggesting
that LEDGINs enhance IN multimerization in the virion,
consistent with previous in vitro data with recombinant
IN [14,16,17,28]. The specificity of this effect of
LEDGINs was further corroborated by examining the
impact of CX05045 on the multimerization of LEDGIN-
resistant HIV-INA128T in the virions produced the same
way as the HIV-INWT particles. HIV-INA128T virus showedcomparable FRET ratio when produced in the presence or
absence of CX05045 with mean FRET ratio of 1.23 (95% CI
1.21-1.24) and 1.26 (95% CI 1.25-1.27), respectively
(Figure 6C). In conclusion, addition of LEDGINs during
virus production enhances IN multimerization, which
results in HIV-1 particles with severe maturation de-
fects and hampered infectivity.
Discussion
LEDGINs, potent allosteric HIV integration inhibitors,
are designed as small molecule PPI inhibitors targeting
the interaction between LEDGF/p75 and IN [12]. By oc-
cupying the LEDGF/p75 binding pocket on the IN dimer
interface, LEDGINs enhance IN multimerization and
therefore allostericly interfere with its catalytic activities
[14,16,17]. In addition we recently reported the late stage
antiviral effect of LEDGINs [16]. However, detailed ana-
lysis and elucidation of the mechanistic basis for the
antiviral effect of LEDGINs in the late stage of HIV-1
replication is essential to guide the further development
of combination therapy including this class of inhibitors
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LEDGF/p75-IN interaction in the late stage of HIV rep-
lication [29].
In a series of experiments we unambiguously demon-
strate that LEDGINs impair the infectivity of progeny vi-
rions through their direct interaction with IN during the
late stage of HIV replication. The infectivity of viruses
produced in the presence of LEDGINs is significantly re-
duced without affecting proteolyic cleavage or gRNA
packaging (Figures 1, 2, 3A). Instead, the severely im-
paired infectivity is attributed to enhanced IN mul-
timerization in progeny virions (Figure 6), resulting in
aberrant core maturation (Figure 3). This leads to abor-
tive reverse transcription and nuclear import steps in
the next replication round (Figures 4–5). In other words,
while LEDGINs block HIV integration, a hallmark
shared with other integrase inhibitors [12,20,30], they
intrinsically also exert an at least equipotent antiviral
activity (Table 1) during the late stage of HIV replica-
tion, which establishes LEDGINs as a unique class of
antiretrovirals.
LEDGINs clearly enhance IN oligomerization in vitro
[12,14,16,17] and in the viral particle (Figure 6B). The
question remains whether the interaction between IN
and LEDGINs may already take place in the configur-
ation of the Pol precursor. This would require Pol
dimerization since the LEDGF/p75 pocket is only
present in the IN dimer. We tried to answer this ques-
tion by performing a Pol dimerization assay in the
AlphaScreen format (Figure 6A). LEDGINs clearly en-
hanced Pol multimerization at nanomolar concentra-
tions. These data suggest that LEDGINs potently induce
Pol dimerization as a result of enhanced IN dimerization
and imply that low amounts of LEDGINs may in fact be
specifically bound to IN in the viral particle.
Initial characterization of the antiviral activity of
LEDGINs demonstrated that they block HIV-1 integra-
tion by disrupting the LEDGF/p75-IN interaction and by
allosteric inhibition of the integrase catalytic activity
[14,16,17]. The data presented here do not only confirm
inhibition at the integration step, but extend the mech-
anism of action of LEDGINs to late stages of HIV repli-
cation. Modulation of the equilibrium of IN multimers
in the virions by LEDGINs is likely to perturb their dy-
namics in the viral particle with deleterious conse-
quences for core formation during the maturation
process. Consistent with results obtained with two other
LEDGINs recently presented by Yant and co-workers
[31] CX05045 treatment of the producer cells prevented
the assembly of regular electron-dense cores in two
thirds of the virions and almost half of those displayed
an abnormal core with an external ribonucleoprotein
(RNP) usually attached to the viral membrane. These ir-
regular particles and the virions that manage to form amorphologically normal core are able to enter a target
cell, but are defective for RT and nuclear import. The
reported impact of IN alterations on the morphology of
the viral core is not without precedence. The phenotype
of empty cores with misplaced RNP was previously ob-
served with IN mutants [32]. It will be interesting to un-
ravel the underlying mechanism leading to a similar
phenotype in these mutants and in viruses produced in
the presence of LEDGINs.
With respect to modulating IN multimerization
Meehan, et al., previously reported on dominant inter-
ference by green fluorescent protein-tagged IN binding
domain of LEDGF/p75 (GFP-IBD) when overexpressed
in stringent LEDGF/p75 knock-down cells. A durable in-
hibition of HIV replication was attributed to premature
or improper IN multimerization and inhibition of inte-
gration [33]. We propose that the dominant interference
effect of the IBD of LEDGF/p75 in fact extends to the
late stage of HIV replication as well and could contrib-
ute to the near complete inhibition of spreading HIV in-
fections [33]. As such, it is possible that the interaction
between IN and LEDGF/p75 may be required in the late
stage of HIV replication, which is further supported by
the late effect of LEDGF/p75-binding cyclic peptides
identified as specific LEDGF/p75-IN interaction inhibi-
tors [29]. Therefore, the late effect of LEDGINs may
additionally involve a block in the interaction between
LEDGF/p75-IN in the late stage of HIV replication, and
expose LEDGF/p75-stripped IN to proteasomal degrad-
ation in infected cells [33-35]. These mutually non-
exclusive mechanisms await further experimentation.
Our findings hold translational relevance. Recently,
the superior antiviral activity of non-nucleoside reverse
transcriptase inhibitors (NNRTIs) and especially prote-
ase inhibitors (PIs) has been explained by steep dose–re-
sponse curves and cooperativity [36,37]. Positive
cooperativity (slope >1) results in a high instantaneous
inhibitory potential (IIP) of compounds in a single round
HIV-1 infection assay [37]. A Hill coefficient of 3.9 was
reported for CX04328 (LEDGIN 6) [14]. Authors attrib-
uted this value to the multimodal mechanism of
LEDGINs during integration. We likewise observed a
high cooperativity for the late antiviral effect of
LEDGINs (data not shown) and therefore the late effect
of LEDGINs likely contributes to the high cooperativity
observed [14]. Of note, some NNRTIs have been impli-
cated to increase dimerization of Gag-Pol polyproteins
in virus producer cells and prematurely activate PR af-
fecting protein cleavage and virion maturation [38]; this
mechanism possibly contributes to the steep dose–re-
sponse curve of NNRTIs. Unlike other antiretroviral
drugs, viruses generated in the presence of PIs display
defective RT in subsequent infections [39,40], explaining
their high cooperativity. In any case LEDGINs are
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late steps of HIV replication explaining the high
cooperativity of this novel class of antivirals and increas-
ing their clinical potential [36,37]. Interestingly, unlike
NNRTIs [38], LEDGINs do not seem to increase prema-
ture PR activation as no effect on proteolytic cleavage
and virus production was observed. Although LEDGINs
are strong enhancers of Pol multimerization (Figure 6A),
we did not observe an increase in premature PR activa-
tion and processing of precursor viral polyproteins in
the producer cells (Figure 3).
Conclusions
Our results explain the molecular basis of the late effect
of LEDGINs, representing a unique antiviral mechanism.
Although inhibition of integration has received most at-
tention, the late effect of LEDGINs can complement the
effect on integration and shows high cooperativity in re-
ducing productive infection. Given the complexities of
HIV replication, the application of this novel class of in-
hibitors will permit to unravel previously unidentified
but important pathways to further our understanding on
the biology of HIV. Moreover, the multi-step antiviral
mode of action of LEDGINs is a clinically relevant ob-
servation that increases the therapeutic potential of this




The human peripheral blood mononuclear cells were
isolated from anonymous healthy blood donors’ Buffy
coats obtained from the University hospitals Gasthuisberg
Leuven Blood Bank, as approved by the ethical committee
of the University Hospitals Gasthuisberg Leuven.
Reagents
Antiviral compounds. LEDGINs (CX04328, CX05045)
were synthesized by Centre for Drug Design and Devel-
opment (CD3), KU Leuven R&D, Leuven, Belgium.
DS10000, AZT, efavirenz, raltegravir and ritonavir were
obtained from AIDS Research and Reference Reagent
Program, Division of AIDS, NIH).
Antibodies. Anti-β-tubulin (mouse,T-4026, Sigma-
Aldrich, St Louis, MO), anti-HIV-1 CAp24 (mouse, #24-2,
AIDS Research and Reference Reagent Program, Division




293T and HeLaP4 cells were maintained in Dulbecco’s
modified Eagle medium (GIBCO BRL, Merelbeke,
Belgium) supplemented with 8% fetal calf serum (FCS;Sigma-Aldrich, Bornem, Belgium) and 50 μg/ml genta-
micin (GIBCO BRL). MT-4, HuT78, and HuT78IIIB cells
were grown in RPMI 1640 (GIBCO BRL) supplemented
with 12% FCS and 50 μg/ml gentamicin. Human periph-
eral blood mononuclear cells (PBMC) were purified
from fresh buffy coats of anonymous voluntary donors
using Lymphoprep (Axis-Shield PoC AS, Oslo, Norway)
following the manufacturer’s protocol. Subsequently,
PBMC were maintained and stimulated in RPMI 1640
supplemented with 15% FCS, 20 U/ml IL-2 and 10 μg/ml
PHA for three days before use in the infectivity assay. To
prepare human monocyte derived macrophages (MDM),
PBMC were purified as described above. Subsequently
monocytes were isolated from PBMC through depletion of
non-monocytes by MACS Cell Separation Columns
(MACS; Miltenyi Biotec, Leiden, the Netherlands). 2x106
monocytes/well of a 6-well plate were seeded in RPMI
(supplemented with 10% FCS, 100 ng/ml of Macrophage
Colony Stimulating Factor (MCSF) and 50 μg/ml genta-
micin). Differentiation was done for 7 days. All cell lines
were grown in a humidified atmosphere with 5% CO2
at 37°C.
Virus strains
All HIV-1 (NL4.3, IIIB, NL4.3A128T, and HXB2D), HIV-2
(ROD, EHO) and SIVmac251 strains were described be-
fore [12,41]. Virus titer was determined by microscopi-
cally scoring of HIV- induced cytopathic effect (CPE) in
MT-4 cells.
Virus production from chronically infected HuT78 cells
Chronically HIV-1IIIB infected HuT78 cells (here called
HuT78IIIB) were generated by incubating cells with HIV-
1IIIB at a MOI of 0.001-0.01 for at least three weeks;
virus release in the supernatant was monitored by p24
quantification using p24 ELISA (Innogenetics, Ghent,
Belgium). For virus production, HuT78IIIB cells were
washed 3 times with PBS and incubated with different
concentrations of AZT, raltegravir, CX04328, CX05045,
ritonavir or DMSO. 24–36 h post addition of the com-
pounds, cells were washed again twice with PBS and in-
cubated in fresh medium supplemented with the
respective compound for 6 more days and cell-free su-
pernatants were harvested and kept at −80°C until use.
Virus production by transfection
Production of different HIV-1 molecular clones (NL4.3,
NL4.3A128T, HXB2D or YU-2) was carried out by
transfecting 293T cells as described before [42]. Briefly,
5.5×106 cells were plated with 5% FSC supplemented
DMEM and transfected the following day with 20 μg of
plasmid per cell culture dish in OptiMEM without
serum. The transfection mix was added directly on the
cells drop by drop and 6 h posttransfection, the
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cin supplemented OptiMEM with or without raltegravir
(0.03 μM), CX05045 (5 μM) or ritonavir (0.3 μM). 72 h
posttransfection, cell-free supernatants were harvested
and filtered through 0.22 μm filters (Millipore). In selected
cases virus preparations were washed twice times with
PBS using Vivaspin (50 kDa Cut-off, Millipore) while cen-
trifuging at 3,000×g. The third wash was done while
pelleting by ultracentrifugation (27,500 rpm, 2 h, SW28
rotor, Beckman Coulter, Fullerton, CA). The pellets were
resuspended in PBS and the virus aliquots were stored
at −80°C until use.
Analysis of viral genomic RNA packaging
Virus was produced by transfection as described above
using serum-free medium (OptiMEM). 48 h post trans-
fection, supernatants were harvested, filtered through
0.22 μm filters, pelleted by ultracentrifugation (31,000
rpm, 45 minutes, Ti70 rotor, Beckman Coulter, Fuller-
ton, CA), and resuspended in 100 μl PBS. Producer cells
(3x106 cells per condition) were also collected, washed,
and pelleted. Prior to RNA extraction, non-infected
293T cells (1x106) were added to each virus sample to
control for the efficiency of RNA extraction, for cDNA
synthesis and for qPCR quantification normalization.
Total RNA was extracted both from the producer cells
and virus preparations to quantify viral genomic RNA
(gRNA) using Total RNA Mini Kit (BioRad, Nazareth,
Belgium) following the manufacturer’s recommenda-
tions. 5 μg of total RNA was used for cDNA synthesis
using the High capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA). As a negative
control, an equivalent amount of RNA from uninfected
cells was used. Genomic RNA was quantified using
qPCR with primers Gag1 (5'-ATCAAGCAGCCATGCA
AATGTT-3') and Gag2 (5’-CTGAAGGGTACTAGTAGT
TCCTGCTATGTC-3’) and the TaqMan Gag probe (5'-
(FAM)-GACCATCAATGAGGAAGCTGCAGAATGGG
A-(TAMRA)-3'). To determine the relative amount of
gRNA viral transcripts, cDNA corresponding to human
β-actin was amplified and used as an internal control for
normalization. All samples were run in triplicate for 3
minutes at 95°C followed by 40 cycles of 10 seconds at
95°C and 30 seconds at 55°C. Data were analyzed with
iQ5 Optical System Software (BioRad).
HIV replication assays
Equal amounts of viruses normalized for p24 antigen
were used to determine infectivity in different cells (MT-
4, HeLaP4, PBMC and MDM) with or without washing.
To determine the 50% tissue culture infective dose
(TCID50), a serial 5-fold dilution of virus was done in
triplicate on MT-4 cells (96-well format, 3×104 cells per
well). 5 dpi, wells containing infected cells wereidentified by the presence of cytopathic effect (CPE), and
the TCID50 was calculated according to the Spearman-
Karber protocol. Data are presented as relative infectivity
compared to controls (DMSO-treated).
To determine replication capacity we used viruses with
or without washing three times. The viruses were
pelleted by ultracentrifugation (27,5000 rpm for 2 h
using an SW28 rotor, Beckman Coulter). All infection
experiments were performed after normalization for p24
protein. 2×105 HeLaP4 cells were seeded per well in 24-
well plates and infections were carried out the next day
using 2–6 μg of p24 equivalent virus. Cells were lysed,
and HIV Tat-driven beta-galactosidase activity (24 hpi)
and HIV fLuc activity (72 hpi) were quantified using the
β-Gal reporter gene assay (Roche diagnostics, Mannheim,
Germany) and Steady-Glo Luciferase assay (Promega), re-
spectively, according to the manufacturers’ recommenda-
tions. EC50 of the late effect of LEDGINs was determined
using virus produced in the presence of a 2-fold dilu-
tion series of CX05045, raltegravir or ritonavir. DMSO
(vehicle) was included as no-inhibitor control.
To evaluate the kinetics of viral breakthrough, we
infected either MT-4 (50,000 cells per well in 1 ml
medium in a 24-well plate), stimulated PBMC (500,000
cells per well in 500 μl final volume in a 48 well plate)
or 2×106 MDM in 6-well plates with different virus inoc-
ula normalized for p24. Virus replication was monitored
by quantifying p24 level in the supernatants on succes-
sive days using p24 ELISA (Innogenetics).
HIV-1 entry assay
For the entry assay, 3×106 MT-4 cells were infected with
HIV-1IIIB virus produced in the presence of 25 μM of
CX05045 or DMSO after normalization for p24 in the
presence or absence of 7 μg/ml of DS10000 or 1.5 μM of
efavirenz. Cells were incubated with the inhibitors 1 h
before infection. Heat inactivated virus was also used as
a negative control. Infection was synchronized by incu-
bating cells at 4°C for 1 h and then transferred to 37°C
incubator for 2 h. 2 hpi cells were pelleted and treated
with trypsin for 60 seconds to remove viruses attached
on the surface of cells, and washed three times with PBS.
Total RNA extraction, cDNA synthesis and real-time
qPCR quantification were performed as described above.
Time-of-addition
Time-of-addition (TOA) was done in MT-4 cells as de-
scribed previously [19]. Briefly, 100,000 cells per well in
a 96-well plate were infected with HIV-1IIIB at a multi-
plicity of infection (MOI) of 0.7. Test compounds were
used at 50-fold EC50 and added every hpi. Cell-free virus
released in the supernatant was harvested at 31 hpi.
While two-thirds (100 μl) of the harvested supernatants
were stored at −80°C to examine the replication capacity
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TOA experiment, the remaining supernatants were used
to determine the target blocked by each antivirals in the
TOA experiment using p24 ELISA (Innogenetics).
To examine the replication capacity of the viruses re-
leased in the TOA experiment, we infected new cells
(MT-4 cells, 50,000 per well in a 96-well plate) with nor-
malized inocula for p24 level for those time points
where a measurable p24 was detected (e.g., AZT, beyond
4 hpi; raltegravir and CX05045, beyond 8 h and all time
points for DMSO-treated viruses). In all cases, we made
sure that the estimated concentration of carryover com-
pound to be 50-fold less than the established EC50 values
of the inhibitors. 4 days postinfection, supernatants were
collected and p24 antigen was quantified using p24 ELISA.
Quantitative PCR analysis of HIV-1 DNA species
MT-4 cells (3.5x106 cells per well in 6-well plates) were
infected with HIV-1IIIB produced in the presence of
DMSO or 25 μM CX05045 (equivalent of 3.5 μg of p24).
The harvested viruses were three times washed with PBS
and pelleted as described above. During the qPCR ex-
periment, we added AZT (EC50 = 0.02 μM), efavirenz
(EC50 = 0.0015 μM) or raltegravir (EC50 = 0.006 μM) at
a concentration of 50- to 100-fold their EC50 values as
controls for inhibition of RT or integration, respectively.
After 2 h of incubation at 37°C, the cells were washed
three times with PBS and incubated in fresh medium
supplemented with the respective inhibitors. Each time a
sample was prepared for qPCR analysis, the supernatant
was harvested to monitor the viral replication by p24
ELISA. DNA extractions and quantification of the kinet-
ics of early and late reverse transcripts, 2-long terminal
repeat (LTR) circles and integrants were done as de-
scribed earlier [18,43].
In vivo PIC nuclear import assay
The PIC nuclear import assay was performed as de-
scribed before [27]. In brief, 6×106 293T cells were
transfected using PEI with 15 μg of pVpr-IN-eGFP,
15 μg of pD64E (pNL4.3 clone containing the IND64E in-
activating mutation obtained from the AIDS Reference
and Reagent Program), and 5 μg of pVSV.G. 6 h post-
transfection, the transfection medium was replaced with
fresh 0% OptiMEM (supplemented with 50 μg/ml genta-
micin) with or without 5-fold EC50 of CX05045. Super-
natants were collected 48 h post transfection, filtered
through a 0.45 μm filter, and then concentrated by ultra-
centrifugation. Virus inocula equivalent to 250 ng of p24
were used to infect 30,000 HeLaP4 cells/well in 8-chamber
slides. 7 hpi, cells were briefly incubated with trypsin
(30 sec), fixed with 4% paraformaldehyde and perme-
abilized with 0.1% Triton-X100 solution in PBS prior to
overnight immunostaining of the nuclear lamina withA/C antibody (1/250, Santa Cruz, sc7292). After staining
with secondary goat anti-mouse antibody labeled with
Alexa Fluor 633 (Molecular Probes) cells were kept in
PBS for imaging. Three-dimensional stacks (300 nm per
Z-slice) of fixed cells were acquired with a Zeiss LSM
510 laser-scanning confocal microscope using a 63× oil
immersion objective. Before quantification, samples were
blinded. Multichannel images were contrast stretched
(linearly) and assembled and fluorescently labeled PICs
(total and nuclear) were quantified using ImageJ soft-
ware (NIH).
Single virus FRET assay
Functional fluorescent HIV-1 particles were produced as
described above in the in vivo PIC nuclear import assay
section with the following modifications: (i) instead of
Vpr-IN-eGFP, virions were produced by co-transfecting
293T cells with 3.75 μg of pD64E, 1.25 μg of Vpr-IN-
mTFP1 (FRET donor) and 1.25 μg of Vpr-IN-mVenus
(FRET acceptor) per well in 6 well plate format, (ii) 6 h
post transfection, the transfection mix was removed and
replaced with fresh medium supplemented with DMSO
or a 5-fold EC50 value of either CX05045 or raltegravir,
and (iii) viruses were harvested 36 h post transfection,
filtered through a 0.45 μm filter and kept at −80°C until
use. For the single virus FRET assay, virus preparations
were incubated for 3 h at 37°C on a poly-D-lysine
(Sigma-Aldrich NV, Bornem, Belgium) coated #1 cover-
glass (Lab-Tek Chambered Coverglass, VWR Inter-
national bvba, Leuven, Belgium), washed with PBS (Life
Technologies Europe BV, Gent, Belgium) and fixed with
10% formalin (Sigma-Aldrich NV, Bornem, Belgium).
Single virus Förster resonance energy transfer (FRET)
measurements were carried out on a total internal re-
flection fluorescence (TIRF) microscope (Olympus IX-71,
Olympus NV, Aartselaar, Belgium). The IN-mTFP1 was
imaged by objective-type TIRF (PlanApo, 60x, NA 1.45,
Olympus) excitation at 150 μW of 445 nm laser light
(Cube 445-40c, Coherent, Utrecht, The Netherlands) and
wide field detection on an electron multiplying-CCD
(ImagEM, Hamamatsu, Louvain-La-Neuve, Belgium) after
filtering the mTFP1 emission (HQ485/40 m, Chroma
Technology GmbH, Olching, Germany). The IN-mVenus
was instantaneously photobleached by 3 mW of 514 nm
laser light (Sapphire 514, 100 mW Coherent), after which
the IN-mTFP1 was immediately imaged again. FRET was
quantified on a single virus basis by super-resolution 2D
Gaussian localization of individual virions and extracting
the ratio of integrated fluorescence intensity per virion after
(FD) vs. before (FDA) photobleaching: FRET ratio = FD/FDA.
FRET ratios for many (~1-5×103) individual virions were
binned in a histogram that was fitted with a normal dis-
tribution. Analysis was performed in Igor (WaveMetrics,
Inc., Portland, OR, USA). This same protocol was followed
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cept, instead of the wild type IN, we used Vpr-INA128T-
mTFP1 (FRET donor) and Vpr-INA128T-mVenus (FRET ac-
ceptor). To test the statistical significance of the data, single
virus FRET ratios were used as input for a Student’s t-test
with unequal variance. A detailed description of this assay
will be subject of another publication (Borrenberghs et al.,
unpublished results).
Cloning of the Pol bacterial expression construct
The synthetic HIV-1IIIB Pol coding sequence was ampli-
fied by PCR from the pcDNA3.1_syn-Gag-Pol construct




AGTCCTCGTCCTGCCTGG-3’) contained attB1 and
B2 sites allowing the product to be Gateway cloned into
pDONR221 (Invitrogen). Next, a D25N substitution was
introduced in PR to render it catalytically dead. Site-
directed Ligase-Independent Mutagenesis (SLIM) [45]




CTTCAGCTGGCCACC-3’ resulting in pDONR221_
sPol_PRD25N. pDONR221_sPol_PRD25N was recombined
with pGGWA and pHMGWA (for which we acknowledge
Busso et al. [46]) in an LR Gateway reaction producing
pGGWA_sPol_PRD25N and pHMGWA_sPol_PRD25N. All
constructs were verified by DNA sequencing.
Purification of recombinant proteins
pGGWA_sPol_PRD25N and pHMGWA_sPol_PRD25N were
used to transform competent E. coli BL21 Star cells
(Invitrogen). Briefly, cells were grown to an OD of 0.5, at
which point protein production was induced with 0.1 mM
Isopropyl β-D-1-thiogalactopyranoside and allowed to
continue for 2 h at 25°C. Cells were harvested, lysed and
GST-sPol_PRD25N and His-MBP-sPol-PRD25N were affinity
purified over Glutathione Sepharose 4 Fast Flow (GE
Healthcare) and over HIS-Select Nickel Affinity gel
(Sigma) respectively, following the manufacturers’ instruc-
tions Purification was monitored via SDS-PAGE and
GST-Pol and His-MBP-Pol appeared as single ~140 kDa
and ~158 kDa bands, respectively, in the elution fractions
after Coomassie staining.
Pol dimerization assay
For Pol dimerization assays we used the AlphaScreen
(PerkinElmer) protein-protein interaction technology is
a bead-based technology that allows to study molecular
interactions as described before [28]. Briefly, all proteins,
compound controls and beads were diluted to theirrespective working stocks in assay buffer (25 mM Tris/
HCl pH 7.5, 150 mM NaCl, 1 mM dithiothreitol, 1 mM
MgCl2 0.1% (w/v) BSA, 0.1% (v/v) Tween 20). 5 μl buffer
or compound, 5 μl GST-sPol-PRD25N and 5 μl His-MBP-
sPol-PRD25N were pipetted in 384-well OptiPlate
(PerkinElmer), mixed and incubated at 4°C for over-
night. Then we added 10 μl of a mix of glutathione donor
and Ni-chelate acceptor AlphaScreen beads (20 μg/ml
final concentration each) and the plate was incubated at
23°C for additional 2 h. Eventually the microtiter plate was
read in an EnVision Multilabel plate reader (PerkinElmer)
and the AlphaScreen signal data were analyzed using
Prism 5.0 (GraphPad). Whereas both GST-sPol-PRD25N
and His-MBP-sPol-PRD25N were kept constant at 33 nM,
the test compounds CX05045, raltegravir or DMSO were
titrated in a 1:10 dilution series starting at 100 μM.
Gel electrophoresis and immunoblot analysis
Protein samples were prepared in 1% SDS. 20 – 30 μg of
total protein in each sample was separated by SDS-
PAGE (4-12%). Proteins were detected with the respec-
tive antibody: rabbit anti-LEDGF/p75 (1:1000 for cell
lysate, Bethyl Laboratories. Inc), mouse monoclonal anti-
HIV-1 IN (IN2, 1:10,000 for viral lysates and 1:2000 for
cell lysates, Abcam), mouse anti-HIV-1 CA (1:10,000,
AIDS reagents Program). Visualization was performed
using chemiluminescence (ECL+, Amersham Biosciences,
Uppsala, Sweden).
Electron microscopy
HUT78IIIB cells were counted and washed twice with
PBS and grown in the presence of DMSO or 25-fold
EC50 of inhibitor (raltegravir, CX05045 or ritonavir) for
24 to 36 h. Subsequently, cells were washed twice with
PBS and incubated with fresh medium with or without
the indicated compounds. After 6 days cells were
harvested, pelleted, and fixed with 2.5% glutaraldehyde
overnight at 4°C. Cell pellets were post-fixed with OsO4
(1% in ddH2O; Plano, Wetzlar, Germany), block-stained
with uranyl acetate (2% in ddH2O; Merck, Darmstadt,
Germany), dehydrated stepwise in graded alcohol,
immersed in propylenoxide and embedded in Epon
(Serva, Heidelberg) with polymerisation at 60°C for 48 h.
Ultrathin sections (60–80 nm) were cut using an ultra-
microtome (Ultracut S or UCT; Leica, Germany) and
stained with 2% uranyl acetate and lead citrate. Trans-
mission electron microscopy was performed with an EM
902 (Zeiss) operated at 80 kV and the images were
digitised using a slow-scan charge-coupled-device cam-
era (Pro Scan; Scheuring, Germany).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5.0 (www.graphpad.com/prism). All data points
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comparisons were carried out using Student’s t test, 1-way
or 2-way ANOVA. The cumulative relative frequency dis-
tribution of the eGFP labeled PICs was analyzed using the
two-tailed Kolmogorov-Smirnov test using XLSTAT 2013
for windows (www.xlstat.com).
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